Immunization with the Haemophilus ducreyi hemoglobin receptor HgbA with adjuvant monophosphoryl lipid A protects swine from a homologous but not a heterologous challenge

Infection and Immunity

Volumn 78, Issue 9, 2010, Pages 3763-3772

  Fusco, William G ^a   Afonina, Galyna ^a,d   Nepluev, Igor ^a,d   Cholon, Deborah M ^a   Choudhary, Neelima ^a   Routh, Patricia A ^b   Almond, Glenn W ^b   Orndorff, Paul E ^b   Staats, Herman ^c   Hobbs, Marcia M ^a   Leduc, Isabelle ^a   Elkins, Christopher ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; FREUND ADJUVANT; HEMOGLOBIN A; PHOSPHORYL LIPID A; BACTERIAL PROTEIN; BACTERIAL VACCINE; BACTERIUM ANTIBODY; CARRIER PROTEIN; DRUG DERIVATIVE; HEMOGLOBIN BINDING PROTEIN, BACTERIA; HEMOGLOBIN-BINDING PROTEIN, BACTERIA; IMMUNOLOGICAL ADJUVANT; LIPID A;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HAEMOPHILUS DUCREYI; HISTOLOGY; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; SWINE; ULCUS MOLLE; ANIMAL; BLOOD; GENETICS; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; CARRIER PROTEINS; CHANCROID; ENZYME-LINKED IMMUNOSORBENT ASSAY; HAEMOPHILUS DUCREYI; IMMUNE SERA; IMMUNIZATION; LIPID A; SWINE;

EID: 77956633497     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00217-10     Document Type: Article

References (68)

1. Afonina, G., I. Leduc, I. Nepluev, C. Jeter, P. Routh, G. Almond, P. E. Orndorff, M. Hobbs, and C. Elkins. 2006. Immunization with the Haemophilus ducreyi hemoglobin receptor HgbA protects against infection in the swine model of chancroid. Infect. Immun. 74:2224-2232.
2. Ahmed, H. J., C. Johansson, L. A. Svensson, K. Ahlman, M. Verdrengh, and T. Lagergard. 2002. In vitro and in vivo interactions of Haemophilus ducreyi with host phagocytes. Infect. Immun. 70:899-908.
3. Al-Tawfiq, J. A., K. R. Fortney, B. P. Katz, A. F. Hood, C. Elkins, and S. M. Spinola. 2000. An isogenic hemoglobin receptor-deficient mutant of Haemophilus ducreyi is attenuated in the human model of experimental infection. J. Infect. Dis. 181:1049-1054.
4. Al-Tawfiq, J. A., A. C. Thornton, B. P. Katz, K. R. Fortney, K. D. Todd, A. F. Hood, and S. M. Spinola. 1998. Standardization of the experimental model of Haemophilus ducreyi infection in human subjects. J. Infect. Dis. 178:1684-1687.
5. Baldrick, P., D. Richardson, G. Elliott, and A. W. Wheeler. 2002. Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant. Regul. Toxicol. Pharmacol. 35:398-413.
6. Baldrick, P., D. Richardson, and A. W. Wheeler. 2001. Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPL) adjuvant: a new allergy vaccine for dust mite allergy. Vaccine 20:737-743.
7. Baldrick, P., D. Richardson, S. R. Woroniecki, and B. Lees. 2007. Pollinex Quattro ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy. J. Appl. Toxicol. 27:399-409.
8. Bauer, B. A., M. K. Stevens, and E. J. Hansen. 1998. Involvement of the Haemophilus ducreyi gmhA gene product in lipooligosaccharide expression and virulence. Infect. Immun. 66:4290-4298.
9. Bertholet, S., Y. Goto, L. Carter, A. Bhatia, R. F. Howard, D. Carter, R. N. Coler, T. S. Vedvick, and S. G. Reed. 2009. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 27:7036-7045.
10. Buchanan, S. K., B. S. Smith, L. Venkatramani, D. Xia, L. Esser, M. Palnitkar, R. Chakraborty, D. van der Helm, and J. Deisenhofer. 1999. Crystal structure of the outer membrane active transporter FepA from Escherichia coli. Nat. Struct. Biol. 6:56-63.
11. Casella, C. R., and T. C. Mitchell. 2008. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life Sci. 65:3231-3240.
12. Chimento, D. P., A. K. Mohanty, R. J. Kadner, and M. C. Wiener. 2003. Substrate-induced transmembrane signaling in the cobalamin transporter BtuB. Nat. Struct. Biol. 10:394-401.
13. Cole, L. E., K. L. Toffer, R. A. Fulcher, L. R. San Mateo, P. E. Orndorff, and T. H. Kawula. 2003. A humoral immune response confers protection against Haemophilus ducreyi infection. Infect. Immun. 71:6971-6977.
14. Cornelis, P., and S. Matthijs. 2002. Diversity of siderophore-mediated iron uptake systems in fluorescent pseudomonads: not only pyoverdines. Environ. Microbiol. 4:787-798.
15. Cornelissen, C. N., J. E. Anderson, and P. F. Sparling. 1997. Characterization of the diversity and the transferrin-binding domain of gonococcal transferrin- binding protein 2. Infect. Immun. 65:822-828.
16. Drachenberg, K. J., A. W. Wheeler, P. Stuebner, and F. Horak. 2001. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56:498-505.
17. Elkins, C. 1995. Identification and purification of a conserved heme-regulated hemoglobin-binding outer membrane protein from Haemophilus ducreyi. Infect. Immun. 63:1241-1245.
18. Elkins, C., N. H. Carbonetti, V. A. Varela, D. Stirewalt, D. G. Klapper, and P. F. Sparling. 1992. Antibodies to N-terminal peptides of gonococcal porin are bactericidal when gonococcal lipopolysaccharide is not sialylated. Mol. Microbiol. 6:2617-2628.
19. Elkins, C., K. Yi, B. Olsen, C. Thomas, K. Thomas, and S. Morse. 2000. Development of a serological test for Haemophilus ducreyi for seroprevalence studies. J. Clin. Microbiol. 38:1520-1526.
20. Ferguson, A. D., R. Chakraborty, B. S. Smith, L. Esser, D. van der Helm, and J. Deisenhofer. 2002. Structural basis of gating by the outer membrane transporter FecA. Science 295:1715-1719. (Pubitemid 34202907)
21. Ferguson, A. D., E. Hofmann, J. W. Coulton, K. Diederichs, and W. Welte. 1998. Siderophore-mediated iron transport: crystal structure of FhuA with bound lipopolysaccharide. Science 282:2215-2220.
22. Frisk, A., H. J. Ahmed, E. Van Dyck, and T. Lagergard. 1998. Antibodies specific to surface antigens are not effective in complement-mediated killing of Haemophilus ducreyi. Microb. Pathog. 25:67-75. (Pubitemid 28398977)
23. Garcon, N. 2010. Preclinical development of AS04. Methods Mol. Biol. 626:15-27.
24. Gordon, D. M., T. W. McGovern, U. Krzych, J. C. Cohen, I. Schneider, R. LaChance, D. G. Heppner, G. Yuan, M. Hollingdale, M. Slaoui, et al. 1995. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171:1576-1585.
25. Hammond, G. W., C. J. Lian, J. C. Wilt, and A. R. Ronald. 1978. Comparison of specimen collection and laboratory techniques for isolation of Haemophilus ducreyi. J. Clin. Microbiol. 7:39-43.
26. Hansen, E. J., C. F. Frisch, and K. H. Johnston. 1981. Detection of antibodyaccessible proteins on the cell surface of Haemophilus influenzae type b. Infect. Immun. 33:950-953.
27. Harper, D. M., E. L. Franco, C. Wheeler, D. G. Ferris, D. Jenkins, A. Schuind, T. Zahaf, B. Innis, P. Naud, N. S. De Carvalho, C. M. Roteli-Martins, J. Teixeira, M. M. Blatter, A. P. Korn, W. Quint, and G. Dubin. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757-1765.
28. Harper, D. M., E. L. Franco, C. M. Wheeler, A. B. Moscicki, B. Romanowski, C. M. Roteli-Martins, D. Jenkins, A. Schuind, S. A. Costa Clemens, and G. Dubin. 2006. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247-1255.
29. Hayes, R., K. Schulz, and F. Plummer. 1995. The cofactor effect of genital ulcers on the per-exposure risk of HIV transmission in sub-Saharan Africa. J. Trop. Med. Hyg. 98:1-8.
30. Heppner, D. G., D. M. Gordon, M. Gross, B. Wellde, W. Leitner, U. Krzych, I. Schneider, R. A. Wirtz, R. L. Richards, A. Trofa, T. Hall, J. C. Sadoff, P. Boerger, C. R. Alving, D. R. Sylvester, T. G. Porter, and W. R. Ballou. 1996. Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J. Infect. Dis. 174:361-366.
31. Hiltke, T. J., M. E. Bauer, J. Klesney-Tait, E. J. Hansen, R. S. Munson, Jr., and S. M. Spinola. 1999. Effect of normal and immune sera on Haemophilus ducreyi 35000HP and its isogenic MOMP and LOS mutants. Microb. Pathog. 26:93-102.
32. Ivins, B. E., M. L. Pitt, P. F. Fellows, J. W. Farchaus, G. E. Benner, D. M. Waag, S. F. Little, G. W. Anderson, Jr., P. H. Gibbs, and A. M. Friedlander. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16:1141-1148.
33. Johnston, B. A., H. Eisen, and D. Fry. 1991. An evaluation of several adjuvant emulsion regimens for the production of polyclonal antisera in rabbits. Lab. Anim. Sci. 41:15-21.
34. King, R., J. Gough, A. Ronald, J. Nasio, J. O. Ndinya-Achola, F. Plummer, and J. A. Wilkins. 1996. An immunohistochemical analysis of naturally occurring chancroid. J. Infect. Dis. 174:427-430.
35. Kreiss, J. K., R. Coombs, F. Plummer, K. K. Holmes, B. Nikora, W. Cameron, E. Ngugi, J. O. Ndinya-Achola, and L. Corey. 1989. Isolation of the human immunodeficiency virus from genital ulcers in Nairobi prostitutes. J. Infect. Dis. 160:380-384.
36. Kundi, M. 2007. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev. Vaccines 6:133-140.
37. Lagergard, T., A. Frisk, M. Purven, and L. A. Nilsson. 1995. Serum bactericidal activity and phagocytosis in host defence against Haemophilus ducreyi. Microb. Path. 18:37-51.
38. Leduc, I., K. E. Banks, K. R. Fortney, K. B. Patterson, S. D. Billings, B. P. Katz, S. M. Spinola, and C. Elkins. 2008. Evaluation of the repertoire of the TonB-dependent receptors of Haemophilus ducreyi for their role in virulence in humans. J. Infect. Dis. 197:1103-1109.
39. Liao, H. X., G. J. Cianciolo, H. F. Staats, R. M. Scearce, D. M. Lapple, S. H. Stauffer, J. R. Thomasch, S. V. Pizzo, D. C. Montefiori, M. Hagen, J. Eldridge, and B. F. Haynes. 2002. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF. Vaccine 20:2396-2403.
40. Locher, K. P., B. Rees, R. Koebnik, A. Mitschler, L. Moulinier, J. P. Rosenbusch, and D. Moras. 1998. Transmembrane signaling across the ligandgated FhuA receptor: crystal structures of free and ferrichrome-bound states reveal allosteric changes. Cell 95:771-778.
41. Mallon, F. M., M. E. Graichen, B. R. Conway, M. S. Landi, and H. C. Hughes. 1991. Comparison of antibody response by use of synthetic adjuvant system and Freund complete adjuvant in rabbits. Am. J. Vet. Res. 52:1503-1506.
42. McGuinness, B., A. K. Barlow, I. N. Clarke, J. E. Farley, A. Anilionis, J. T. Poolman, and J. E. Heckels. 1990. Deduced amino acid sequences of class 1 protein (PorA) from three strains of Neisseria meningitidis. Synthetic peptides define the epitopes responsible for serosubtype specificity. J. Exp. Med. 171:1871-1882.
43. Moore, A., L. McCarthy, and K. H. Mills. 1999. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 17:2517-2527.
44. Nepluev, I., G. Afonina, W. G. Fusco, I. Leduc, B. Olsen, B. Temple, and C. Elkins. 2009. An immunogenic, surface-exposed domain of Haemophilus ducreyi outer membrane protein HgbA is involved in hemoglobin binding. Infect. Immun. 77:3065-3074.
45. Odumeru, J. A., G. M. Wiseman, and A. R. Ronald. 1985. Role of lipopolysaccharide and complement in susceptibility of Haemophilus ducreyi to human serum. Infect. Immun. 50:495-499.
46. Paavonen, J., D. Jenkins, F. X. Bosch, P. Naud, J. Salmeron, C. M. Wheeler, S. N. Chow, D. L. Apter, H. C. Kitchener, X. Castellsague, N. S. de Carvalho, S. R. Skinner, D. M. Harper, J. A. Hedrick, U. Jaisamrarn, G. A. Limson, M. Dionne, W. Quint, B. Spiessens, P. Peeters, F. Struyf, S. L. Wieting, M. O. Lehtinen, and G. Dubin. 2007. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161-2170.
47. Plummer, F. A., L. J. D'Costa, H. Nsanze, P. Karasira, I. W. MacLean, P. Piot, and A. R. Ronald. 1985. Clinical and microbiologic studies of genital ulcers in Kenyan women. Sex. Transm. Dis. 12:193-197.
48. Plummer, F. A., J. N. Simonsen, D. W. Cameron, J. O. Ndinya-Achola, J. K. Kreiss, M. N. Gakinya, P. Waiyaki, M. Cheang, P. Piot, A. R. Ronald, and E. N. Ngugi. 1991. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J. Infect. Dis. 163:233-239.
49. Post, D. M., and B. W. Gibson. 2007. Proposed second class of Haemophilus ducreyi strains show altered protein and lipooligosaccharide profiles. Proteomics 7:3131-3142.
50. Post, D. M., R. S. Munson, Jr., B. Baker, H. Zhong, J. A. Bozue, and B. W. Gibson. 2007. Identification of genes involved in the expression of atypical lipooligosaccharide structures from a second class of Haemophilus ducreyi. Infect. Immun. 75:113-121.
51. Ronald, A. R., and F. A. Plummer. 1985. Chancroid and Haemophilus ducreyi. Ann. Intern. Med. 102:705-707.
52. San Mateo, L. R., K. L. Toffer, P. E. Orndorff, and T. H. Kawula. 1999. Neutropenia restores virulence to an attenuated Cu,Zn superoxide dismutase- deficient Haemophilus ducreyi strain in the swine model of chancroid. Infect. Immun. 67:5345-5351.
53. Scheffler, N. K., A. M. Falick, S. C. Hall, W. C. Ray, D. M. Post, R. S. Munson, Jr., and B. W. Gibson. 2003. Proteome of Haemophilus ducreyi by 2-D SDS-PAGE and mass spectrometry: strain variation, virulence, and carbohydrate expression. J. Proteome Res. 2:523-533.
54. Sokal, E. M., K. Hoppenbrouwers, C. Vandermeulen, M. Moutschen, P. Leonard, A. Moreels, M. Haumont, A. Bollen, F. Smets, and M. Denis. 2007. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J. Infect. Dis. 196:1749-1753.
55. Spinola, S. M., A. Orazi, J. N. Arno, K. Fortney, P. Kotylo, C. Y. Chen, A. A. Campagnari, and A. F. Hood. 1996. Haemophilus ducreyi elicits a cutaneous infiltrate of CD4 cells during experimental human infection. J. Infect. Dis. 173:394-402.
56. Spinola, S. M., L. M. Wild, M. A. Apicella, A. A. Gaspari, and A. A. Campagnari. 1994. Experimental human infection with Haemophilus ducreyi. J. Infect. Dis. 169:1146-1150.
57. Stanberry, L. R., S. L. Spruance, A. L. Cunningham, D. I. Bernstein, A. Mindel, S. Sacks, S. Tyring, F. Y. Aoki, M. Slaoui, M. Denis, P. Vandepapeliere, and G. Dubin. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661.
58. Steen, R. 2001. Eradicating chancroid. Bull. World Health Organ. 79:818-826.
59. Stoute, J. A., K. E. Kester, U. Krzych, B. T. Wellde, T. Hall, K. White, G. Glenn, C. F. Ockenhouse, N. Garcon, R. Schwenk, D. E. Lanar, P. Sun, P. Momin, R. A. Wirtz, C. Golenda, M. Slaoui, G. Wortmann, C. Holland, M. Dowler, J. Cohen, and W. R. Ballou. 1998. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. 178:1139-1144.
60. Swanson, J., L. W. Mayer, and M. R. Tam. 1982. Antigenicity of Neisseria gonorrhoeae outer membrane protein(s) III detected by immunoprecipitation and Western blot transfer with a monoclonal antibody. Infect. Immun. 38:668-672.
61. Tong, N. K., J. Beran, S. A. Kee, J. L. Miguel, C. Sanchez, J. M. Bayas, A. Vilella, J. R. de Juanes, P. Arrazola, F. Calbo-Torrecillas, E. L. de Novales, V. Hamtiaux, M. Lievens, and M. Stoffel. 2005. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 68:2298-2303. (Pubitemid 43117807)
62. Trees, D. L., and S. A. Morse. 1995. Chancroid and Haemophilus ducreyi: an update. Clin. Microbiol. Rev. 8:357-375.
63. Vakevainen, M., S. Greenberg, and E. J. Hansen. 2003. Inhibition of phagocytosis by Haemophilus ducreyi requires expression of the LspA1 and LspA2 proteins. Infect. Immun. 71:5994-6003.
64. van der Ley, P., J. E. Heckels, M. Virji, P. Hoogerhout, and J. T. Poolman. 1991. Topology of outer membrane porins in pathogenic Neisseria spp. Infect. Immun. 59:2963-2971.
65. Verstraeten, T., D. Descamps, M. P. David, T. Zahaf, K. Hardt, P. Izurieta, G. Dubin, and T. Breuer. 2008. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 26:6630-6638.
66. Wasserheit, J. 1992. Epidemiological survey. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex. Transm. Dis. 19:61-77.
67. White, C. D., I. Leduc, B. Olsen, C. Jeter, C. Harris, and C. Elkins. 2005. Haemophilus ducreyi outer membrane determinants, including DsrA, define two clonal populations. Infect. Immun. 73:2387-2399.
68. Wood, G. E., S. M. Dutro, and P. A. Totten. 2001. Haemophilus ducreyi inhibits phagocytosis by U-937 cells, a human macrophage-like cell line. Infect. Immun. 69:4726-4733.